Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics (Q36537788)

14 August 2017

1 reference

title

Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics (English)

1 reference

14 August 2017

1 reference

Karl E Krueger

1

1 reference

14 August 2017

Sudhir Srivastava

series ordinal

2

1 reference

14 August 2017

language of work or name

1 reference

14 July 2006

1 reference

Molecular & Cellular Proteomics

14 August 2017

published in

1 reference

14 August 2017

volume

5

1 reference

14 August 2017

issue

10

1 reference

14 August 2017

page(s)

1799-1810

1 reference

Printed covalent glycan array for ligand profiling of diverse glycan binding proteins

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Antibodies immobilized as arrays to profile protein post-translational modifications in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Assays for high-throughput screening of E2 AND E3 ubiquitin ligases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Global analysis of protein phosphorylation in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Themes and variations on ubiquitylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Versatile protein tag, SUMO: its enzymology and biological function

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

On ubiquitin ligases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Ubiquitin ligases in malignant lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Glycan-dependent signaling: O-linked N-acetylglucosamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Role of the retinoblastoma protein in the pathogenesis of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Cyclin D1 and human neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Are RB proteins a potential substrate of Pin1 in the regulation of the cell cycle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Tumor-specific exon 1 mutations could be the 'hit event' predisposing Rb2/p130 gene to epigenetic silencing in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Post-translational modification of p53 in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Acetylation of nuclear receptors in cellular growth and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Regulation of histone deacetylase activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Folate, DNA stability and colo-rectal neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Histone lysine demethylases and their impact on epigenetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

PTEN function: how normal cells control it and tumour cells lose it

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

The role of integrin-linked kinase (ILK) in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Integrin-linked kinase, a promising cancer therapeutic target: biochemical and biological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xe

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Oncogenic Ras in tumour progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Mucins in cancer: protection and control of the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Proteomic profiling of metalloprotease activities with cocktails of active-site probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Modifications of H3 and H4 during chromatin replication, nucleosome assembly, and histone exchange.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Monoclonal and bispecific antibodies as novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Farnesylated proteins as anticancer drug targets: from laboratory to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Proteasome inhibition as a novel therapeutic target in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Vaccination with Theratope (STn-KLH) as treatment for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

FDA drug approval summary: erlotinib (Tarceva) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

Radiation combined with EGFR signal inhibitors: head and neck cancer focus

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

New strategies in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.R600009-MCP200

10.1074/MCP.R600009-MCP200

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference